Ubiquitylation is a reversible post-translational modification involved in a myriad of cellular functions.
A superfamily of approximately 100 ubiquitin-specific proteases, called deubiquitylating enzymes, deubiquitinases or DUBs, remove ubiquitin from target proteins, disassemble polymeric ubiquitin chains and process ubiquitin precursor polypeptides to maintain ubiquitin homeostasis in cells.
Most DUBs are Cys proteases; a small group are metalloproteases.
DUBs are classified into five families (ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases (USPs), Ovarian tumour proteases (OTUs), Josephins and JAB1/MPN/Mov34 metalloenzymes (JAMMs, also known as MPN+) that are structurally unrelated, but all interact with a common hydrophobic patch on ubiquitin.
Multiple layers of regulation modulate the activity and specificity of these enzymes. Specificity also entails recognition of and selective activity towards particular ubiquitin chain types, at least eight of which are now known to coexist in yeast and mammalian cells.
DUBs might function to regulate both the stability and the activity of target proteins, which include oncogenes and tumour suppressors. Their wide-ranging involvement in key regulatory processes makes DUBs attractive targets for drug therapy.
Ubiquitylation is a reversible protein modification that is implicated in many cellular functions. Recently, much progress has been made in the characterization of a superfamily of isopeptidases that remove ubiquitin: the deubiquitinases (DUBs; also known as deubiquitylating or deubiquitinating enzymes). Far from being uniform in structure and function, these enzymes display a myriad of distinct mechanistic features. The small number (<100) of DUBs might at first suggest a low degree of selectivity; however, DUBs are subject to multiple layers of regulation that modulate both their activity and their specificity. Due to their wide-ranging involvement in key regulatory processes, these enzymes might provide new therapeutic targets.
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Peng, J. et al. A proteomics approach to understanding protein ubiquitination. Nature Biotech. 21, 921–926 (2003).
Meierhofer, D., Wang, X., Huang, L. & Kaiser, P. Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry. J. Proteome Res. 10, 4566–4576 (2008).
Ikeda, F. & Dikic, I. Atypical ubiquitin chains: new molecular signals. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep. 9, 536–542 (2008).
Scheel, H. Comparative Analysis of the Ubiquitin-Proteasome System in Homo sapiens and Saccharomyces cerevisiae. Thesis, Univ. Cologne (2005). Highly comprehensive bioinformatic study of the ubiquitin–proteasome system, which deserves a wide readership.
Nijman, S. M. et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773–786 (2005).
Hurley, J. H., Lee, S. & Prag, G. Ubiquitin-binding domains. Biochem. J. 399, 361–372 (2006).
Zhu, X., Menard, R. & Sulea, T. High incidence of ubiquitin-like domains in human ubiquitin-specific proteases. Proteins 69, 1–7 (2007).
Edelmann, M. J. & Kessler, B. M. Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: emerging patterns and molecular principles. Biochim. Biophys. Acta 1782, 809–816 (2008).
Komander, D. & Barford, D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem. J. 409, 77–85 (2008).
Storer, A. C. & Menard, R. Catalytic mechanism in papain family of cysteine peptidases. Methods Enzymol. 244, 486–500 (1994).
Hu, M. et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111, 1041–1054 (2002). The first USP domain structure, in the presence and absence of ubiquitin. It defined the USP fold and revealed conformational changes on ubiquitin binding.
Reyes-Turcu, F. E., Shanks, J. R., Komander, D. & Wilkinson, K. D. Recognition of polyubiquitin isoforms by the multiple ubiquitin binding modules of isopeptidase T. J. Biol. Chem. 283, 19581–19592 (2008).
Hu, M. et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 24, 3747–3756 (2005).
Avvakumov, G. V. et al. Amino-terminal dimerization, NRDP1–rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J. Biol. Chem. 281, 38061–38070 (2006).
Komander, D. et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol. Cell 29, 451–464 (2008). Provides a rationale for the Lys63-linked ubiquitin chain specificity of CYLD.
Edelmann, M. J. et al. Structural basis and specificity of human otubain 1-mediated deubiquitination. Biochem. J. 418, 379–390 (2009).
Lin, S. C. et al. Molecular basis for the unique deubiquitinating activity of the NF-κB inhibitor A20. J. Mol. Biol. 376, 526–540 (2008).
Nanao, M. H. et al. Crystal structure of human otubain 2. EMBO Rep. 5, 783–788 (2004).
Messick, T. E. et al. Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein. J. Biol. Chem. 283, 11038–11049 (2008).
Johnston, S. C., Larsen, C. N., Cook, W. J., Wilkinson, K. D. & Hill, C. P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 A resolution. EMBO J. 16, 3787–3796 (1997).
Johnston, S. C., Riddle, S. M., Cohen, R. E. & Hill, C. P. Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J. 18, 3877–3887 (1999).
Komander, D. et al. Molecular discrimination of structurally equivalent Lys63-linked and linear polyubiquitin chains. EMBO Rep. 5, 466–473 (2009). First survey of ubiquitin chain linkage specificities across DUB families.
Popp, M. W., Artavanis-Tsakonas, K. & Ploegh, H. L. Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. J. Biol. Chem. 284, 3593–3602 (2009). The active site crossover loop in UCHL3 requires extension to allow polyubiquitin chain cleavage.
Larsen, C. N., Krantz, B. A. & Wilkinson, K. D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37, 3358–3368 (1998).
Riess, O., Rub, U., Pastore, A., Bauer, P. & Schols, L. SCA3: neurological features, pathogenesis and animal models. Cerebellum 7, 125–137 (2008).
Nicastro, G. et al. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc. Natl Acad. Sci. USA 102, 10493–10498 (2005). Together with references 27 and 28, this paper reveals the large conformational changes exhibited by the Josephinfamily of DUBs.
Mao, Y. et al. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc. Natl Acad. Sci. USA 102, 12700–12705 (2005).
Nicastro, G. et al. The josephin domain of ataxin-3 contains two distinct ubiquitin binding motifs. Biopolymers 20 Apr 2009 (doi:10.1002/bip.21210).
Sato, Y. et al. Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains. Nature 455, 358–362 (2008). The first structure of a DUB with a diubiquitin bound across the active site. It revealed the mechanism of action of JAMM/MPN+ proteases and suggested a rationale for the Lys63-linked ubiquitin chain specificity of AMSH-LP.
Tran, H. J., Allen, M. D., Lowe, J. & Bycroft, M. Structure of the Jab1/MPN domain and its implications for proteasome function. Biochemistry 42, 11460–11465 (2003).
Maytal-Kivity, V., Reis, N., Hofmann, K. & Glickman, M. H. MPN+, a putative catalytic motif found in a subset of MPN domain proteins from eukaryotes and prokaryotes, is critical for Rpn11 function. BMC Biochem. 3, 28 (2002).
Yao, T. & Cohen, R. E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419, 403–407 (2002).
Cope, G. A. et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298, 608–611 (2002).
McCullough, J. et al. Activation of the endosome-associated ubiquitin isopeptidase AMSH by STAM, a component of the multivesicular body-sorting machinery. Curr. Biol. 16, 160–165 (2006).
Dong, Y. et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell 12, 1087–1099 (2003).
Wang, B. & Elledge, S. J. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc. Natl Acad. Sci. USA 104, 20759–20763 (2007).
Shao, G. et al. The Rap80–BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8–Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc. Natl Acad. Sci. USA 106, 3166–3171 (2009).
Cooper, E. M. et al. K63-specific deubiquitination by two JAMM/MPN+ complexes: BRISC-associated Brcc36 and proteasomal Poh1. EMBO J. 28, 621–631 (2009).
Drag, M. et al. Positional-scanning fluorigenic substrate libraries reveal unexpected specificity determinants of DUBs (deubiquitinating enzymes). Biochem. J. 415, 367–375 (2008).
Catic, A. et al. Screen for ISG15-crossreactive deubiquitinases. PLoS ONE 2, e679 (2007).
Frias-Staheli, N. et al. Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe 2, 404–416 (2007).
Malakhov, M. P., Malakhova, O. A., Kim, K. I., Ritchie, K. J. & Zhang, D. E. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem. 277, 9976–9981 (2002).
Gong, L., Kamitani, T., Millas, S. & Yeh, E. T. Identification of a novel isopeptidase with dual specificity for ubiquitin- and NEDD8-conjugated proteins. J. Biol. Chem. 275, 14212–14216 (2000).
Tokunaga, F. et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nature Cell Biol. 11, 123–132 (2009).
Rahighi, S. et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 136, 1098–1109 (2009).
Huang, T. T. et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nature Cell Biol. 8, 339–347 (2006).
Wang, T. et al. Evidence for bidentate substrate binding as the basis for the K48 linkage specificity of otubain 1. J. Mol. Biol. 386, 1011–1023 (2009).
Tran, H., Hamada, F., Schwarz-Romond, T. & Bienz, M. Trabid, a new positive regulator of Wnt-induced transcription with preference for binding and cleaving K63-linked ubiquitin chains. Genes Dev. 22, 528–542 (2008).
Kayagaki, N. et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 318, 1628–1632 (2007).
McCullough, J., Clague, M. J. & Urbe, S. AMSH is an endosome-associated ubiquitin isopeptidase. J. Cell Biol. 166, 487–492 (2004). First direct demonstration of in vitro chain linkage specificity and proposed function in regulating receptor fate.
Nakamura, M., Tanaka, N., Kitamura, N. & Komada, M. Clathrin anchors deubiquitinating enzymes, AMSH and AMSH-like protein, on early endosomes. Genes Cells 11, 593–606 (2006).
Winborn, B. J. et al. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J. Biol. Chem. 283, 26436–26443 (2008).
Al-Hakim, A. K. et al. Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains. Biochem. J. 411, 249–260 (2008).
Reyes-Turcu, F. E. et al. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell 124, 1197–1208 (2006). Defines a new mode of ubiquitin recognition and allosteric regulation of DUB activity.
Amerik, A., Swaminathan, S., Krantz, B. A., Wilkinson, K. D. & Hochstrasser, M. In vivo disassembly of free polyubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome. EMBO J. 16, 4826–4838 (1997).
Hunter, T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 28, 730–738 (2007).
Reiley, W., Zhang, M., Wu, X., Granger, E. & Sun, S. C. Regulation of the deubiquitinating enzyme CYLD by IκB kinase gamma-dependent phosphorylation. Mol. Cell. Biol. 25, 3886–3895 (2005).
Mizuno, E., Kitamura, N. & Komada, M. 14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase. Exp. Cell Res. 313, 3624–3634 (2007).
Pohl, C. & Jentsch, S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell 132, 832–845 (2008).
Mukai, A. et al. Dynamic regulation of ubiquitylation and deubiquitylation at the central spindle during cytokinesis. J. Cell Sci. 121, 1325–1333 (2008).
Todi, S. V. et al. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J. 28, 372–382 (2009).
Meulmeester, E., Kunze, M., Hsiao, H. H., Urlaub, H. & Melchior, F. Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol. Cell 30, 610–619 (2008).
Ross, S. H. et al. Differential redox regulation within the PTP superfamily. Cell Signal. 19, 1521–1530 (2007).
Enesa, K. et al. Hydrogen peroxide prolongs nuclear localization of NF-κB in activated cells by suppressing negative regulatory mechanisms. J. Biol. Chem. 283, 18582–18590 (2008). Suggests that DUBs of the NF-κB pathway might be targets of reactive oxygen species.
Coornaert, B. et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nature Immunol. 9, 263–271 (2008).
Row, P. E. et al. The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation. J. Biol. Chem. 282, 30929–30937 (2007).
Iha, H. et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-κB activation. EMBO J. 27, 629–641 (2008).
Wagner, S. et al. Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene 27, 3739–3745 (2008).
Yao, T. et al. Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex. Mol. Cell 31, 909–917 (2008).
Kimura, Y. et al. An inhibitor of a deubiquitinating enzyme regulates ubiquitin homeostasis. Cell 137, 549–559 (2009).
Ventii, K. H. & Wilkinson, K. D. Protein partners of deubiquitinating enzymes. Biochem. J. 414, 161–175 (2008).
Cohn, M. A. et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell 28, 786–797 (2007). Together with reference 73, this paper shows that a WD40 protein can allosterically activate three DUBs of the USP family.
Cohn, M. A., Kee, Y., Haas, W., Gygi, S. P. & D'Andrea, A. D. UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J. Biol. Chem. 8, 5343–5351 (2008).
Sowa, M. E., Bennett, E. J., Gygi, S. P. & Harper, J. W. Defining the human deubiquitinating enzyme interaction landscape. Cell 16 Jul 2009 (doi: 10.1016/j.cell.2009.04.042). Comprehensive proteomic study of the interaction profiles of 75 human DUBs.
van der Knaap, J. A. et al. GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Mol. Cell 17, 695–707 (2005).
Row, P. E., Prior, I. A., McCullough, J., Clague, M. J. & Urbe, S. The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation. J. Biol. Chem. 281, 12618–12624 (2006).
Blagoev, B., Ong, S. E., Kratchmarova, I. & Mann, M. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nature Biotech. 22, 1139–1145 (2004).
Nakamura, N. & Hirose, S. Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane. Mol. Biol. Cell 19, 1903–1911 (2008).
Endo, A. et al. Nucleolar structure and function are regulated by the deubiquitylating enzyme USP36. J. Cell Sci. 122, 678–686 (2009).
Lauwers, E., Jacob, C. & Andre, B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J. Cell Biol. 3, 493–502 (2009).
Xu, P. et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137, 133–145 (2009).
Daviet, L. & Colland, F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 90, 270–283 (2008).
Nicholson, B., Marblestone, J. G., Butt, T. R. & Mattern, M. R. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 3, 191–199 (2007).
Hoeller, D. & Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature 458, 438–444 (2009).
Graner, E. et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5, 253–261 (2004). This paper, together with references 86 and 87, highlights the potential relevance of DUBs as therapeutic drug targets.
Popov, N. et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nature Cell Biol. 9, 765–774 (2007).
Cummins, J. M. & Vogelstein, B. HAUSP is required for p53 destabilization. Cell Cycle 3, 689–692 (2004).
Stegmeier, F. et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 446, 876–881 (2007). Highlights the crucial role for USP44 in the progression of the cell cycle.
Huang, F., Kirkpatrick, D., Jiang, X., Gygi, S. & Sorkin, A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol. Cell 21, 737–748 (2006).
Clague, M. J. & Urbe, S. Endocytosis: the DUB version. Trends Cell Biol. 16, 551–559 (2006).
Butterworth, M. B. et al. The deubiquitinating enzyme UCH-L3 regulates the apical membrane recycling of the epithelial sodium channel. J. Biol. Chem. 282, 37885–37893 (2007).
Mizuno, E., Kobayashi, K., Yamamoto, A., Kitamura, N. & Komada, M. A deubiquitinating enzyme UBPY regulates the level of protein ubiquitination on endosomes. Traffic 7, 1017–1031 (2006).
Boulkroun, S. et al. Vasopressin-inducible ubiquitin-specific protease 10 increases ENaC cell surface expression by deubiquitylating and stabilizing sorting nexin 3. Am. J. Physiol. Renal Physiol. 295, F889–F900 (2008).
Li, Z. et al. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 277, 4656–4662 (2002).
Lu, Y. et al. USP19 deubiquitinating enzyme supports cell proliferation by stabilizing KPC1, a ubiquitin ligase for p27Kip1. Mol. Cell Biol. 29, 547–558 (2009).
Cao, Z., Wu, X., Yen, L., Sweeney, C. & Carraway, K. L. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol. Cell. Biol. 27, 2180–2188 (2007).
Brummelkamp, T. R., Nijman, S. M., Dirac, A. M. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424, 797–801 (2003). Together with references 98 and 99, this study put the spotlight on the tumour suppressor function of a DUB.
Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424, 793–796 (2003).
Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424, 801–805 (2003).
Brooks, C. L., Li, M., Hu, M., Shi, Y. & Gu, W. The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 26, 7262–7266 (2007).
Heyninck, K. & Beyaert, R. A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem. Sci. 30, 1–4 (2005).
Verma, R. et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298, 611–615 (2002).
Koulich, E., Li, X. & Demartino, G. N. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol. Biol. Cell 19, 1072–1082 (2008).
Crosas, B. et al. Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities. Cell 127, 1401–1413 (2006).
Leggett, D. S. et al. Multiple associated proteins regulate proteasome structure and function. Mol. Cell 10, 495–507 (2002).
Yao, T. et al. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nature Cell Biol. 8, 994–1002 (2006).
Hanna, J., Meides, A., Zhang, D. P. & Finley, D. A ubiquitin stress response induces altered proteasome composition. Cell 129, 747–759 (2007).
Hanna, J. et al. Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell 127, 99–111 (2006).
Amerik, A. Y., Nowak, J., Swaminathan, S. & Hochstrasser, M. The DoA4 deubiquitinating enzyme is functionally linked to the vacuolar protein-sorting and endocytic pathways. Mol. Biol. Cell 11, 3365–3380 (2000).
Dayal, S. et al. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J. Biol. Chem. 8, 5030–5041 (2008).
Amerik, A. Y., Li, S. J. & Hochstrasser, M. Analysis of the deubiquitinating enzymes of the yeast Saccharomyces cerevisiae. Biol. Chem. 381, 981–992 (2000).
Kirkin, V. & Dikic, I. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr. Opin. Cell Biol. 19, 199–205 (2007).
Mueller, R. D., Yasuda, H., Hatch, C. L., Bonner, W. M. & Bradbury, E. M. Identification of ubiquitinated histones 2A and 2B in Physarum polycephalum. Disappearance of these proteins at metaphase and reappearance at anaphase. J. Biol. Chem. 260, 5147–5153 (1985).
Zhu, P. et al. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol. Cell 27, 609–621 (2007).
Joo, H. Y. et al. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 449, 1068–1072 (2007).
Nicassio, F. et al. Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr. Biol. 22, 1972–1977 (2007).
Zhang, X. Y. et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol. Cell 29, 102–111 (2008).
Nijman, S. M. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331–339 (2005). A nice example of the application of an siRNA library screen to identify USP1 as a regulator of FANCD2.
Oestergaard, V. H. et al. Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol. Cell 28, 798–809 (2007).
Chiu, Y. H., Zhao, M. & Chen, Z. J. Ubiquitin in NF-κB signaling. Chem. Rev. 4, 1549–1560 (2009).
Sun, S. C. Deubiquitylation and regulation of the immune response. Nature Rev. Immunol. 8, 501–511 (2008).
Boone, D. L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nature Immunol. 5, 1052–1060 (2004).
Lee, E. G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350–2354 (2000).
Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009).
Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712–716 (2009).
Schmitz, R. et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 5, 981–989 (2009).
Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694–699 (2004). First description of ubiquitin chain editing by a DUB.
Shembade, N. et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nature Immunol. 9, 254–262 (2008).
Shembade, N., Parvatiyar, K., Harhaj, N. S. & Harhaj, E. W. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-κB signalling. EMBO J. 5, 513–522 (2009).
Enesa, K. et al. NF-κB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J. Biol. Chem. 283, 7036–7045 (2008).
Dupont, S. et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFβ signaling, controls Smad4 monoubiquitination. Cell 136, 123–135 (2009).
Burrows, J. F. et al. USP17 regulates Ras activation and cell proliferation by blocking RCE 1 activity. J. Biol. Chem. 14, 9587–9595 (2009).
Rigden, D. J., Liu, H., Hayes, S. D., Urbé, S. & Clague, M. J. Ab initio protein modelling reveals novel human MIT domains. FEBS Lett. 583, 872–878 (2009).
Burrows, J. F., McGrattan, M. J. & Johnston, J. A. The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence. Genomics 85, 524–529 (2005).
Quesada, V. et al. Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases. Biochem. Biophys. Res. Commun. 314, 54–62 (2004).
Pena, V., Liu, S., Bujnicki, J. M., Luhrmann, R. & Wahl, M. C. Structure of a multipartite protein-protein interaction domain in splicing factor prp8 and its link to retinitis pigmentosa. Mol. Cell 25, 615–624 (2007).
Misaghi, S. et al. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J. Biol. Chem. 280, 1512–1520 (2005).
Ye, Y., Scheel, H., Hofmann, K. & Komander, D. Dissection of USP catalytic domains reveals five common insertion points. Mol. Biosyst. 17 Jul 2009 (doi:10.1039/b907669g)
We thank K. Hofmann and D. Rigden for bioinformatic discussions and advice. S.U. is a Cancer Research UK Senior Research Fellow.
Supplementary information S9 (table) | Analysis of the linkage context for all types of polyubiquitin chains. (PDF 170 kb)
An enzyme that requires a metal ion, such as zinc, for its activity and catalytic mechanism. The positive charge of the metal is used to position components of the reaction cycles.
- Zinc finger ubiquitin-specific protease domain
(ZnF-UBP domain). A zinc finger that is present in histone deacetylase 6 and several ubiquitin-specific proteases, and which in some but not all cases has been shown to bind ubiquitin.
- Ubiquitin-associated domain
(UBA domain). A short (40 amino acid) sequence motif, first found in proteins associated with the ubiquitylation pathway, that mediates (poly)ubiquitin binding.
- Ubiquitin-like fold
(UBL fold). Ubiquitin contains a distinct three-dimensional fold, which has been used in many proteins related to the ubiquitin system and also in unrelated proteins.
A domain found in microtubule-interacting and trafficking proteins that forms a three-helix bundle. Some MIT domains, including those of AMSH and USP8, bind to charged multi-vesicular body proteins.
The log10 acid dissociation constant. The pKa of a given molecule corresponds to the pH value at which its acid and conjugate base forms are balanced.
- Acyl intermediate
An intermediate in the Cys DUB reaction mechanism, in which the DUB is covalently bound to the C terminus of the distal ubiquitin. A sulphur acyl bond is formed between the C-terminal Gly of ubiquitin and the catalytic Cys of the DUB.
- Oxy-anion hole
Found next to the catalytic Cys of a DUB, this environment stabilizes the negative charge that is created during the transition state before the formation of the acyl intermediate, by supplying hydrogen-donating amide groups, for example on Asn or Gln.
Used here in the context of DUB cleavage to refer to the relative position of ubiquitin moieties in a ubiquitin chain; in a ubiquitin dimer, distal corresponds to the ubiquitin molecule that is conjugated through its C-terminal Gly.
A small zinc-binding fold resembling a RING domain, but lacking E3 ligase activity. It is frequently found in the tripartite motif (TRIM) ubiquitin E3 ligases in a conserved array consisting of RING, B-box and coiled coil domains. The function is unknown.
- Machado–Joseph disease
(MJD). A rare hereditary ataxia — that is, a disease characterized by lack of muscle control — also called spinocerebrellar ataxia type 3. The name derives from two families of Portuguese and Azorean descent, who were among the first patients described.
- 26S proteasome
A large multisubunit protease complex that selectively degrades multi-ubiquitylated proteins. It contains a 20S particle, which incorporates three distinct proteolytic activities, and one or two regulatory 19S particles.
- COP9 signalosome
An eight-subunit protein complex that regulates protein ubiquitylation and turnover in various developmental and physiological contexts. Extensively characterized in plants but fundamental to all eukaryotes, this complex post-translationally modifies the cullin subunit of E3 ubiquitin ligases by cleaving off the covalently coupled peptide NEDD8.
- ESCRT machinery
(Endosomal sorting complex required for transport). A multimeric protein complex that was first identified biochemically in yeast. The ESCRT machinery controls the sorting of endosomal cargo proteins into internal vesicles of multivesicular bodies.
- 14-3-3 proteins
A family of regulatory proteins that bind to phosphorylated forms of various proteins, which are involved in signal transduction and cell cycle control.
- Catalytic rate
The number of substrate molecules that are converted into a product by an enzyme molecule in a unit of time, when the enzyme is fully saturated with substrate.
- WD40 domain
A domain consisting of 4–10 WD40 repeats of 44–60 amino acids, which assemble into a propeller-shaped scaffold. Many distinct protein- and peptide-binding sites have been described in these adaptor domains.
A subnuclear electron-dense structure composed of protein and nucleic acids that has a key role in the biogenesis of ribosomal RNA.
- Early endosome
(Also known as sorting endosome). A tubular, vesicular structure that receives material directly from the plasma membrane and is a precursor of the mature (late) endosome. Early endosomes have a key role in sorting material for recycling or degradation in lysosomes.
A membrane-bound organelle in higher eukaryotic cells that has an acidic interior and is the major storage site of the degradative enzymes (acidic hydrolases) that are responsible for the breakdown of internalized proteins and many membrane proteins. It is functionally equivalent to the yeast vacuole.
About this article
Cite this article
Komander, D., Clague, M. & Urbé, S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550–563 (2009). https://doi.org/10.1038/nrm2731
USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc
Journal of Experimental & Clinical Cancer Research (2021)
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer
Acta Pharmacologica Sinica (2021)
Cell Death & Differentiation (2021)
Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
Cell Death & Differentiation (2021)
Signal Transduction and Targeted Therapy (2021)